- Home
- MULN vs APLM Comparison
MULN vs APLM Comparison
Compare MULN & APLM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MULN
- APLM
- Stock Information
- Founded
- MULN 2014
- APLM 2016
- Country
- MULN United States
- APLM United States
- Employees
- MULN N/A
- APLM N/A
- Industry
- MULN Auto Manufacturing
- APLM Blank Checks
- Sector
- MULN Consumer Discretionary
- APLM Finance
- Exchange
- MULN Nasdaq
- APLM Nasdaq
- Market Cap
- MULN 6.5M
- APLM 6.9M
- IPO Year
- MULN N/A
- APLM N/A
- Fundamental
- Price
- MULN $0.62
- APLM $6.41
- Analyst Decision
- MULN
- APLM
- Analyst Count
- MULN 0
- APLM 0
- Target Price
- MULN N/A
- APLM N/A
- AVG Volume (30 Days)
- MULN 8.0M
- APLM 4.6K
- Earning Date
- MULN 08-11-2025
- APLM 08-13-2025
- Dividend Yield
- MULN N/A
- APLM N/A
- EPS Growth
- MULN N/A
- APLM N/A
- EPS
- MULN N/A
- APLM N/A
- Revenue
- MULN $8,931,612.00
- APLM $198,000.00
- Revenue This Year
- MULN N/A
- APLM $415.15
- Revenue Next Year
- MULN N/A
- APLM N/A
- P/E Ratio
- MULN N/A
- APLM N/A
- Revenue Growth
- MULN 2136.62
- APLM N/A
- 52 Week Low
- MULN $0.59
- APLM $4.47
- 52 Week High
- MULN $154,200,000.00
- APLM $35.98
- Technical
- Relative Strength Index (RSI)
- MULN 20.72
- APLM 51.61
- Support Level
- MULN $1.62
- APLM $5.34
- Resistance Level
- MULN $1.64
- APLM $6.70
- Average True Range (ATR)
- MULN 0.91
- APLM 0.52
- MACD
- MULN 152.97
- APLM -0.03
- Stochastic Oscillator
- MULN 0.66
- APLM 67.65
About MULN Mullen Automotive Inc.
Mullen Automotive Inc is engaged in manufacturing electric vehicles and building energy solutions. Its portfolio of vehicles is predominantly comprised of commercial trucks and other electric vehicles and includes; Mullen Class 1 Cargo Van, Mullen Three, Bollinger B4 Chassis Cab, and Mullen I-GO. The company's operating segments are Bollinger which derives maximum revenue, and Mullen Commercial.
About APLM Apollomics Inc.
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia.